US › Healthcare

Neurogene Inc (NGNE)

US · Healthcare · Biotechnology

$34.41+4.69%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-30.9M
Profit YoY
-36.6%
EPS
$-1.39
EPS estimate
$-1.27

EPS came in at -1.39 against a street estimate of -1.27 — a miss of 9.1%.

Key statistics

Market cap
$656.2M
Forward P/E
0.0
P/B
2.75
Book value
$15.23
EPS (TTM)
$-4.55
52-week high
$43.66
52-week low
$15.93
50-day MA
$32.18
200-day MA
$25.27
Beta
1.96

Analyst view

Analysts rate Neurogene Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $81.71.

Shareholding

Insiders
7.07%
Institutions
88.51%

Largest institutional holders

FundStake
Samsara BioCapital, LLC8.61%
Redmile Group, LLC7.32%
Casdin Capital, LLC7.12%
RTW INVESTMENTS, LLC6.83%
EcoR1 Capital, LLC6.37%
BlackRock Inc5.04%
Baker Bros Advisors LP4.97%
Trails Edge Capital Partners, LP3.92%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Neurogene Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.